Cargando…
PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy
Oncogenic PI3K/mTOR activation is frequently observed in human cancers and activates cell motility via p27 phosphorylations at T157 and T198. Here we explored the potential for a novel PI3K/mTOR inhibitor to inhibit tumor invasion and metastasis. An MDA-MB-231 breast cancer line variant, MDA-MB-231-...
Autores principales: | Wander, Seth A., Zhao, Dekuang, Besser, Alexandra H., Hong, Feng, Wei, Jianqin, Ince, Tan A., Milikowski, Clara, Bishopric, Nanette H., Minn, Andy J., Creighton, Chad J., Slingerland, Joyce M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608882/ https://www.ncbi.nlm.nih.gov/pubmed/23430223 http://dx.doi.org/10.1007/s10549-012-2389-6 |
Ejemplares similares
-
Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy
por: Wander, Seth A., et al.
Publicado: (2016) -
Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
por: Bostner, Josefine, et al.
Publicado: (2012) -
p27 transcriptionally coregulates cJun to drive programs of tumor progression
por: Yoon, Hyunho, et al.
Publicado: (2019) -
Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
por: He, Jichao, et al.
Publicado: (2019) -
A novel RNA aptamer identifies plasma membrane ATP synthase beta subunit as an early marker and therapeutic target in aggressive cancer
por: Speransky, S., et al.
Publicado: (2019)